Perspective from Mary Norine Walsh, MD, MACC
Source:

Press Release

Disclosures: Solomon reports he received institutional research grants and consultant fees from multiple pharmaceutical companies, including Novartis.
February 16, 2021
2 min read
Save

Sacubitril/valsartan receives expanded indication, including for some with HFpEF

Perspective from Mary Norine Walsh, MD, MACC
Source:

Press Release

Disclosures: Solomon reports he received institutional research grants and consultant fees from multiple pharmaceutical companies, including Novartis.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Novartis announced the FDA has granted an expanded indication for sacubitril/valsartan to lower risk for CV death and HF hospitalization in adult patients with chronic HF.

The indication covers certain patients with HF with preserved ejection fraction but does not specify a cutoff left ventricular EF.

Approved
Source: Adobe Stock

According to a press release from the company, the benefits of sacubitril/valsartan (Entresto, Novartis) are greatest among patients with HF and LVEF below normal.

The new indication was based in data from the PARAGON-HF trial.

As Healio previously reported, in PARAGON-HF, sacubitril/valsartan was not superior to valsartan for the reduction of CV death and HF hospitalization events among patients with LVEF at least 45%; however, certain groups did experience a benefit, including women and patients with EF equal to or below the median of 57%.

The company stated in the release that the new indication makes sacubitril/valsartan the first medication to be approved for use both in patients with HF with reduced ejection fraction and in certain patients with HFpEF.

According to the release, the new label will mention that LVEF is a variable measure and that clinical judgment is necessary to determine whether a patient should be prescribed the drug.

Scott Solomon

“This approval is a significant advancement, providing a treatment to many patients who were not eligible for treatment before because their ejection fraction was above the region we normally considered reduced. Until now, treatment for these patients was largely empiric,” Scott Solomon, MD, professor of medicine at Harvard Medical School and Brigham and Women's Hospital and co-chair of the PARAGON-HF executive committee, said in the release. “We can now offer a treatment to a wider range of patients who have an LVEF below normal.”